ATE357247T1 - Inhibitoren von autoantikörpern - Google Patents

Inhibitoren von autoantikörpern

Info

Publication number
ATE357247T1
ATE357247T1 AT99949555T AT99949555T ATE357247T1 AT E357247 T1 ATE357247 T1 AT E357247T1 AT 99949555 T AT99949555 T AT 99949555T AT 99949555 T AT99949555 T AT 99949555T AT E357247 T1 ATE357247 T1 AT E357247T1
Authority
AT
Austria
Prior art keywords
inhibitors
autoantibodies
pathogenic
autoantibody
mog
Prior art date
Application number
AT99949555T
Other languages
English (en)
Inventor
Claude P Genain
Stephen L Hauser
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE357247T1 publication Critical patent/ATE357247T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
AT99949555T 1998-08-26 1999-08-26 Inhibitoren von autoantikörpern ATE357247T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9795398P 1998-08-26 1998-08-26

Publications (1)

Publication Number Publication Date
ATE357247T1 true ATE357247T1 (de) 2007-04-15

Family

ID=22265911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99949555T ATE357247T1 (de) 1998-08-26 1999-08-26 Inhibitoren von autoantikörpern

Country Status (8)

Country Link
US (2) US6333033B1 (de)
EP (1) EP1115425B1 (de)
JP (1) JP2002523472A (de)
AT (1) ATE357247T1 (de)
AU (1) AU6240299A (de)
CA (1) CA2341240C (de)
DE (1) DE69935603T2 (de)
WO (1) WO2000012126A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410506B1 (en) * 1995-05-19 2002-06-25 Human Genome Sciences, Inc. Transforming growth factor α HII
US6569431B2 (en) * 2000-10-17 2003-05-27 The Regents Of The University Of California Recombinant antibody fragments as autoantibody antagonists
ITFI20010114A1 (it) 2001-06-22 2002-12-22 Univ Firenze Glicopeptidi,loro preparazione e loro uso nella diagnosi o nel trattamento terapeutico della sclerosi multipla
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US20050009096A1 (en) * 2002-10-11 2005-01-13 The Regents Of The University Of California Method for diagnosis and prognosis of multiple sclerosis
US20050272097A1 (en) * 2004-02-18 2005-12-08 Emanuel Calenoff Methods and compositions for detecting and treating autoimmune diseases
CA2698541C (en) * 2007-10-19 2018-01-09 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
WO2012045324A1 (en) * 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
EP3560955A4 (de) * 2016-12-26 2020-12-23 Kyowa Kirin Co., Ltd. Antikörper, der in der lage ist, an das myelin-oligodendrozyten-glycoprotein zu binden
US20240167042A1 (en) * 2021-04-09 2024-05-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Development of aptamers for neutralizing antibodies in demyelinating diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
KR960705038A (ko) * 1993-09-03 1996-10-09 스테시 엘. 채닝 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)
WO1995007096A1 (en) 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
AU5671196A (en) * 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof

Also Published As

Publication number Publication date
WO2000012126A1 (en) 2000-03-09
CA2341240C (en) 2008-04-01
DE69935603T2 (de) 2007-12-06
EP1115425A4 (de) 2005-01-26
JP2002523472A (ja) 2002-07-30
US6573236B2 (en) 2003-06-03
DE69935603D1 (de) 2007-05-03
CA2341240A1 (en) 2000-03-09
US6333033B1 (en) 2001-12-25
EP1115425B1 (de) 2007-03-21
US20020068058A1 (en) 2002-06-06
EP1115425A1 (de) 2001-07-18
AU6240299A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
ATE357247T1 (de) Inhibitoren von autoantikörpern
ATE225772T1 (de) Thrombin-inhibitoren
DE69620161D1 (de) Thrombininhibitoren
PT873340E (pt) Compostos heterociclicos de ciclopentano substituido
ATE262915T1 (de) Zusammensetzungen zur verstärkung zytoprotektiver wirkung von polycyclischer phenolverbindungen durch synergistiche wechselwirkung von antioxidationsmitteln
DE69840025D1 (de) Assoziierter antworten
DE69841020D1 (de) HLA-E Bindung zu CD94/NKG2+ Zellen
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
EA200000868A1 (ru) Ингибиторы фосфолипаз
FI941580A0 (fi) Bisyklisiä ansamysiinejä
AP9901674A0 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
ATE287402T1 (de) Nanomolare, non-peptidische inhibitoren von cathepsin d
WO1999019513A3 (en) Methods for detecting compounds which modulate the activity of an lpa receptor
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
AU1314300A (en) Methods and compositions for inhibiting polymerization of ethylenically unsaturated hydrocarbons
WO2002064840A3 (en) Methods for identifying compounds that inhibit or reduce ptp1b expression
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
EA200000522A1 (ru) 5-htагонисты
WO2002086065A3 (en) Induction of apoptosis by cellular stress
NZ292369A (en) Protein and coding sequence for ciita transcription activation domain and methods for identifying compounds inhibiting it and this inhibiting mhc class ii gene expression
WO2000021516A3 (en) Methods for inhibiting diabetic complications
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE244305T1 (de) Verfahren zur modulation der t-zell- überlebensrate durch von bcl-xl protein-spiegels
CY1105675T1 (el) Πρωτεϊνη ροσδενουσα αγγειοστατινη
WO2004065932A3 (en) Methods of identifying modulators of cellular glycosylation using gtrap3-18

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties